/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Bristol-Myers Squibb Company (BMY), headquartered in Princeton, New Jersey, is a leading biopharmaceutical company focused on developing treatments for serious diseases such as cancer, inflammatory, immunologic, cardiovascular, and fibrotic diseases. Valued at $83.1 billion by market cap, its strong oncology portfolio includes blockbuster drug Opdivo and other drugs like Revlimid, Pomalyst, Sprycel, Yervoy, and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis.
Companies worth $10 billion or more are generally described as “large-cap stocks,” BMY fits right into that category, signifying its substantial size, stability, and dominance in its industry. Bristol-Myers Squibb's prominent position in the pharma industry results from its well-established brand reputation, extensive research and development capabilities, varied product portfolio, and worldwide presence. The company's dedication to innovation and delivering high-quality products has enabled it to develop numerous groundbreaking drugs.